美国哮喘患者使用吸入性皮质类固醇/长效β2-激动剂（氟替卡松糠酸酯/维兰特罗或布地奈德/福莫特罗）控制症状的回顾性匹配队列研究

数据集获取（Figshare）

• 源站标题：Symptom control in patients with asthma using inhaled corticosteroids/long-acting β₂-agonists (fluticasone furoate/vilanterol or budesonide/formoterol) in the US: a retrospective matched cohort study
• DOI：10.6084/m9.figshare.16437505.v1
• 发布日期：2021-08-25
• 文件数：3 个
• 文件总体积：59.95 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Symptom_control_in_patients_with_asthma_using_inhaled_corticosteroids_long-acting_sub_2_sub_-agonists_fluticasone_furoate_vilanterol_or_budesonide_formoterol_in_the_US_a_retrospective_matched_cohort_study/16437505

命令行下载

curl -L -o "ijas_a_1963767_sm4828.docx" "https://ndownloader.figshare.com/files/30447802"
curl -L -o "ijas_a_1963767_sm4827.docx" "https://ndownloader.figshare.com/files/30447805"
curl -L -o "ijas_a_1963767_sm4826.docx" "https://ndownloader.figshare.com/files/30447808"

文件清单

• ijas_a_1963767_sm4828.docx（16.25 KB）
• ijas_a_1963767_sm4827.docx（21.89 KB）
• ijas_a_1963767_sm4826.docx（21.80 KB）

文件总体积 59.95 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Treatment with fluticasone furoate/vilanterol (FF/VI), an inhaled corticosteroid/long-acting β2-agonist therapy, reduces the risk of severe asthma exacerbations and improves lung function and symptom control in patients with asthma. However, real-world data remain limited among asthma patients in the United States (US).
This retrospective cohort study propensity score (PS) matched adult asthma patients initiating once-daily FF/VI 100/25 mcg with patients initiating twice-daily budesonide/formoterol (B/F) 160/4.5 mcg using a US claims database (January 1, 2015–December 31, 2018). Asthma control was measured by the mean number of short-acting β2-agonist (SABA) canisters dispensed per patient-year (PPY) during follow-up. Time to first, and rates of, overall and severe asthma exacerbations were also measured.
After PS matching, 18,531 patients receiving FF/VI were matched to 18,531 patients receiving B/F. Mean SABA canisters dispensed PPY was significantly lower for FF/VI users compared with B/F users (FF/VI: 1.47, B/F: 1.64; p p p = 0.027). Asthma-related exacerbation rates per 100 patient-days were also significantly lower for the FF/VI group compared with the B/F group (overall: 0.0475 vs. 0.0558, p p = 0.020).
In real-world practice, initiation of once-daily FF/VI 100/25 mcg in adults with asthma was associated with lower use of SABA and fewer asthma-related exacerbations, which may indicate better asthma control, when compared with use of twice-daily B/F 160/4.5 mcg.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.16437505.v1（source: https://tandf.figshare.com/articles/dataset/Symptom_control_in_patients_with_asthma_using_inhaled_corticosteroids_long-acting_sub_2_sub_-agonists_fluticasone_furoate_vilanterol_or_budesonide_formoterol_in_the_US_a_retrospective_matched_cohort_study/16437505）。